

PRESS RELEASE

Piramal Pharma Solutions Honors its Riverview, Michigan and Digwal, India Facilities with the Annual Excellence in Patient Centricity Award

- *This Award recognizes the facilities that exemplified Piramal Pharma Solutions' patient-centric values through unique projects and initiatives.*
- *For the first time in the Company's history, two facilities have been named co-winners of this prestigious Award.*

Mumbai, India | October 16, 2025: Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), has proudly selected its drug substance facilities in Riverview, Michigan and Digwal, India as the winners of its Annual Award for Excellence in Patient Centricity.

To reinforce its commitment to Patient Centricity, Piramal Pharma Solutions established Patient Awareness Councils (PACs) across its 15 global sites. These PACs organize engaging initiatives and programs that educate employees about the Company's core values and enhance their connection to the patients they serve. Each year, the PACs nominate one of their programs for the Excellence in Patient Centricity Award. This year, for the first time in the Company's history, both the Riverview, Michigan and Digwal, India sites were jointly recognized for their contributions.

The Riverview PAC was honored for paying tribute to Patient Centricity with a stunning mural entitled, "The PAC Tree." Conceptualized by the group and hand-painted by one of its talented members, the PAC Tree provides a visual representation of the site's shared commitment to patient-centric values.



By offering every employee and visitor the chance to add their thumbprint "leaf" to the mural, the PAC Tree fosters a sense of personal ownership and dedication to Patient Centricity, while serving as a constant reminder of everyone's vital role in the patient journey. So far, over 90% of Riverview employees have participated in the mural, and its design has been used on branded merchandise, promoting Patient Centricity beyond Riverview's walls.

The Digwal PAC was named co-winner of the Award for their significant contributions in expanding patient access to a prescription medication used to treat overactive bladder (OB) that was previously only available to adult women. A single-patient need sparked the Digwal facility – which supplies 90% of the global API for the medication – to undertake the challenge of securing approvals for male use of the treatment to address a broader, unmet medical need. To achieve this feat, the Digwal PAC organized 16 Patient Centricity refresher trainings, helping 350 employees reconnect with the “why” behind their work. By doing so, the PAC sparked a renewed sense of ownership and pride across Regulatory, QA, Production, Supply Chain, and Medical Affairs. This enabled the Digwal team to reduce regulatory and supply timelines by 20%, culminating in secured EU approvals and the fortification of a secure, consistent supply of this groundbreaking therapy for more patients in need.



“Our PACs transform Patient Centricity from concept to conduct. By instilling our core values across our community and beyond, they ensure our work makes a meaningful difference in patients’ lives,” said **Stuart Needleman, Chief Commercial Officer and Chief Patient Centricity Officer, Piramal Pharma Solutions**. “We are especially proud of the Riverview and Digwal PACs for strengthening our shared vision with their innovative initiatives and look forward to witnessing the lasting impact of their efforts.”

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private Limited.

For more information visit: [Piramal Pharma Solutions](#) | [LinkedIn](#) | [Facebook](#) | [X](#)

About Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the

Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: [Piramal Pharma](#) | [LinkedIn](#)

* Includes one facility via PPL's minority investment in Yapan Bio.

For Investor Queries:

Gagan Borana

Investor Relations & Enterprise Risk Management

gagan.borana@piramal.com

For Media Queries:

Madiha Vahid

Lead – Branding & Communications

madiha.vahid@piramal.com